In a regulatory filing, Caris Life Sciences (CAI) vice chairman Brian Brille disclosed the purchase of 30,000 common shares of the company on June 20 at a price of $21 per share.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Opening Day: Caris jumps as investors buy into ‘AI TechBio company’
- Two new option listings and nine option delistings on June 23rd
- Caris Life Sciences 23.53M share IPO priced at $21.00
- Caris Life Sciences indicated to open at $30, IPO priced at $21 per share
- Caris Life Sciences indicated to open at $28.50, IPO priced at $21